Fulvestrant (‘Faslodex’) in heavily pretreated postmenopausal patients with advanced breast cancer: single centre clinical experience from the compassionate use programme
Authors:
- 13 February 2007
- journal article
- clinical trial
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 106 (1) , 105-112
Abstract
Fulvestrant (Faslodex) is an oestrogen receptor (ER) antagonist with demonstrated efficacy in patients with advanced and pretreated breast cancer. We present a single-centre experience with fulvestrant administered under the compassionate use programme (CUP) to a total of 54 postmenopausal women with metastatic breast cancer progressing on multiple endocrine and cytotoxic therapies. Patients received 250 mg fulvestrant i.m. once monthly as second- (n = 8), third- (n = 30), fourth- (n = 14) and fifth-line (n = 2) hormonal treatment. The median number of previous endocrine therapies was 2 (range 1–4). Most of the patients also had multiple palliative chemotherapies with a median of 1.7 (range 0–6) prior therapies. The median duration of fulvestrant treatment was 6.3 months (range 1–39 months) and the median duration of follow-up was 19.4 months (range 1–63 months). Objective response was achieved by five patients (9.3%): one complete remission (CR) (1.9%) and four partial remissions (PR) (7.4%). Stable disease (SD) lasting ≥6 months was achieved by 16 patients (29.6%). Thus in all, fulvestrant conferred clinical benefit (CB) on 21 women (38.9%). The median time to progression (TTP) was 6.4 months. In all patients with CR and PR, tumour cells were positive for both ER and progesterone receptor (PgR), but lacked HER2/neu overexpression; one patient with PR had an unknown HER2/neu status. Overall, the drug was well tolerated. No grade 3/4 toxicities were reported. Fulvestrant appears to be an efficient and well-tolerated drug even in women with advanced breast cancer progressing after multiple endocrine and/or cytotoxic treatments.Keywords
This publication has 18 references indexed in Scilit:
- Compliance and toxicity of adjuvant CMF in elderly breast cancer patients: a single-center experienceBMC Cancer, 2005
- Breast Cancer With Synchronous Metastases: Trends in Survival During a 14-Year PeriodJournal of Clinical Oncology, 2004
- Interobserver and Intraobserver Variability in Measurement of Non–Small-Cell Carcinoma Lung Lesions: Implications for Assessment of Tumor ResponseJournal of Clinical Oncology, 2003
- Double-Blind, Randomized Trial Comparing the Efficacy and Tolerability of Fulvestrant Versus Anastrozole in Postmenopausal Women With Advanced Breast Cancer Progressing on Prior Endocrine Therapy: Results of a North American TrialJournal of Clinical Oncology, 2002
- Fulvestrant, Formerly ICI 182,780, Is as Effective as Anastrozole in Postmenopausal Women With Advanced Breast Cancer Progressing After Prior Endocrine TreatmentJournal of Clinical Oncology, 2002
- ICI 182,780 (Faslodex?)Cancer, 2000
- Quality of life in patients with metastatic breast cancer receiving either docetaxel or sequential methotrexate and 5-fluorouracil. A multicentre randomised phase III trial by the Scandinavian Breast GroupEuropean Journal of Cancer, 2000
- Comparison of Two Quality-of-Life Instruments for Cancer Patients: The Functional Assessment of Cancer Therapy-General and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30Journal of Clinical Oncology, 1999
- Influence of Antiestrogens on the Invasiveness and Laminin Attachment of Breast Cancer CellsCancer Investigation, 1999
- Patient acceptance and differential perceptions of quality of life measures in a French oncology settingQuality of Life Research, 1992